Columbia researchers have discovered how a genetic defect leads to spinal muscular atrophy, a finding that could lead to a new therapy for a disease that affects 1 in 6,000 children.
Columbia’s researchers have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier, enabling higher concentrations of an effective drug to enter the brain.